Shaw LM - Search Results

1

Topical application of WR-2721 achieves high concentrations in the rectal wall.

Ben-Josef E, Mesina J, Shaw LM, Bonner HS, Shamsa F, Porter AT. Ben-Josef E, et al. Among authors: shaw lm. Radiat Res. 1995 Jul;143(1):107-10. Radiat Res. 1995. PMID: 7597137

2

A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.

Ben-Josef E, Han S, Tobi M, Shaw LM, Bonner HS, Vargas BJ, Prokop S, Stamos B, Kelly L, Biggar S, Kaplan I. Ben-Josef E, et al. Among authors: shaw lm. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1160-4. doi: 10.1016/s0360-3016(02)02883-3. Int J Radiat Oncol Biol Phys. 2002. PMID: 12128116

3

Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography.

Bonner HS, Shaw LM. Bonner HS, et al. Among authors: shaw lm. J Chromatogr B Biomed Sci Appl. 2000 Mar 10;739(2):357-62. doi: 10.1016/s0378-4347(99)00523-x. J Chromatogr B Biomed Sci Appl. 2000. PMID: 10755379

4

Human pharmacokinetics of WR-2721.

Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, Kligerman MM. Shaw LM, et al. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1501-4. doi: 10.1016/0360-3016(86)90203-8. Int J Radiat Oncol Biol Phys. 1986. PMID: 3019968 Free article.

5

Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys.

Levi M, Knol JA, Ensminger WD, DeRemer SJ, Dou C, Lunte SM, Bonner HS, Shaw LM, Smith DE. Levi M, et al. Among authors: shaw lm. Drug Metab Dispos. 2002 Dec;30(12):1425-30. doi: 10.1124/dmd.30.12.1425. Drug Metab Dispos. 2002. PMID: 12433814

6

Pharmacokinetics of WR-2721.

Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH, Kligerman MM. Shaw LM, et al. Pharmacol Ther. 1988;39(1-3):195-201. doi: 10.1016/0163-7258(88)90061-7. Pharmacol Ther. 1988. PMID: 2849123 Review. No abstract available.

7

Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.

Shaw LM, Bonner HS, Brown DQ. Shaw LM, et al. Drug Metab Dispos. 1994 Nov-Dec;22(6):895-902. Drug Metab Dispos. 1994. PMID: 7895607

8

New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.

Bonner HS, Shaw LM. Bonner HS, et al. Among authors: shaw lm. J Clin Pharmacol. 2002 Feb;42(2):166-74. doi: 10.1177/00912700222011201. J Clin Pharmacol. 2002. PMID: 11831539 Clinical Trial.

9

Pharmacokinetic profile of amifostine.

Shaw LM, Bonner H, Lieberman R. Shaw LM, et al. Semin Oncol. 1996 Aug;23(4 Suppl 8):18-22. Semin Oncol. 1996. PMID: 8783662 Review.

10

A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer.

Huang K, Vaughn DJ, Shaw LM, Recio A, Bonner HS, Haller DG. Huang K, et al. Among authors: shaw lm. Am J Clin Oncol. 1998 Dec;21(6):548-52. doi: 10.1097/00000421-199812000-00004. Am J Clin Oncol. 1998. PMID: 9856653 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

752 results

Search Page

Filters